CALR and autoimmune disease: At this regard, the work of Zhou et al96 describes 21 patients who developed autoimmune disease‐related autoantibodies to anti‒SSA/Ro antibody in 45% and antinuclear antibody in 50% of cases, all benefiting from immunosuppressive therapy.